Hepatitis C virus inhibitors

Patent metadata

Field	Value
Publication number	US-9227940-B2
Application number	US-201414477594-A
Country	US
Kind code	B2
Filing date	Sep 4, 2014
Priority date	May 20, 2002
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

Hepatitis C virus inhibitors are disclosed having the general formula:

wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

First claim

What is claimed is:

1. A method for treating a patient infected with Hepatitis C Virus, the method comprising administering to the patient a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 further comprising administering an additional antiviral agent prior to, currently with, or following the administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

Assignees

• Bristol Myers Squibb Co

Inventors

• Wang Alan Xiangdong
• Sun Li-Qiang
• Sit Sing-Yuen
• Sin Ny
• Scola Paul Michael
• Chen Yan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/04

  Immunostimulants · CPC title